229 related articles for article (PubMed ID: 28244062)
41. Erythema multiforme major in a patient with metastatic melanoma treated with nivolumab.
Sundaresan S; Nguyen KT; Nelson KC; Ivan D; Patel AB
Dermatol Online J; 2017 Sep; 23(9):. PubMed ID: 29469720
[TBL] [Abstract][Full Text] [Related]
42. BRAF Inhibitor-Induced Antitumoral Granulomatous Dermatitis Eruption in Advanced Melanoma.
Garrido MC; Gutierrez C; Riveiro-Falkenbach E; Ortiz P; Rodriguez-Peralto JL
Am J Dermatopathol; 2015 Oct; 37(10):795-8. PubMed ID: 26381028
[TBL] [Abstract][Full Text] [Related]
43. [Severe panuveitis in a metastatic cutaneous melanoma patient treated with vemurafenib].
Boiché M; Conart JB; Angioi-Duprez K
J Fr Ophtalmol; 2018 Jun; 41(6):e291-e292. PubMed ID: 29908650
[No Abstract] [Full Text] [Related]
44. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
45. Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management.
Hwang SJ; Anforth R; Carlos G; Fernandez-Peñas P
Actas Dermosifiliogr; 2017; 108(1):6-16. PubMed ID: 27642030
[TBL] [Abstract][Full Text] [Related]
46. Facial spiny follicular hyperkeratosis induced by vemurafenib.
Nieto Rodríguez D; Gómez Fernández C; Rueda Carnero JM
J Dermatol; 2018 Feb; 45(2):e43-e44. PubMed ID: 28971523
[No Abstract] [Full Text] [Related]
47. Dabrafenib-associated necrobiotic granulomatous reaction.
Carlos G; Anforth R; Chou S; Fernandez-Peñas P
Australas J Dermatol; 2014 Nov; 55(4):306-8. PubMed ID: 25399793
[No Abstract] [Full Text] [Related]
48. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma.
Pattanaprichakul P; Tetzlaff MT; Lapolla WJ; Torres-Cabala CA; Duvic M; Prieto VG; Tsai KY; Curry JL
J Cutan Pathol; 2014 Mar; 41(3):326-8. PubMed ID: 24372055
[No Abstract] [Full Text] [Related]
49. Panniculitis in association with apomorphine infusion.
Acland KM; Churchyard A; Fletcher CL; Turner K; Lees A; Dowd PM
Br J Dermatol; 1998 Mar; 138(3):480-2. PubMed ID: 9580803
[TBL] [Abstract][Full Text] [Related]
50. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
Galliker NA; Murer C; Kamarashev J; Dummer R; Goldinger SM
Eur J Dermatol; 2015 Apr; 25(2):177-80. PubMed ID: 25788221
[TBL] [Abstract][Full Text] [Related]
51. Necrotizing vasculitis due to gefitinib (Iressa).
Fernández-Guarino M; Ryan AM; Pérez-García B; Gónzalez-López C; Olasolo PJ
Int J Dermatol; 2007 Aug; 46(8):890-1. PubMed ID: 17651185
[No Abstract] [Full Text] [Related]
52. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
Alloo A; Garibyan L; LeBoeuf N; Lin G; Werchniak A; Hodi FS; Flaherty KT; Lawrence DP; Lin JY
Arch Dermatol; 2012 Mar; 148(3):363-6. PubMed ID: 22431777
[TBL] [Abstract][Full Text] [Related]
53. Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.
Perret RE; Josselin N; Knol AC; Khammari A; Cassecuel J; Peuvrel L; Dreno B;
Int J Dermatol; 2017 May; 56(5):527-533. PubMed ID: 28188628
[TBL] [Abstract][Full Text] [Related]
54. Sweet's syndrome--like neutrophilic lobular panniculitis associated with all-trans-retinoic acid chemotherapy in a patient with acute promyelocytic leukemia.
Jagdeo J; Campbell R; Long T; Muglia J; Telang G; Robinson-Bostom L
J Am Acad Dermatol; 2007 Apr; 56(4):690-3. PubMed ID: 17367621
[TBL] [Abstract][Full Text] [Related]
55. Cutaneous granulomatous panniculitis and sarcoidal granulomatous papular eruption in a patient with metastatic melanoma treated with a BRAF inhibitor.
Leal L; Agut-Busquet E; Romani J; Sabat M; Yebenes M; Saez A; Luelmo J
J Dermatol; 2016 Jun; 43(6):715-6. PubMed ID: 26777901
[No Abstract] [Full Text] [Related]
56. Vasculitis and panniculitis associated with vemurafenib.
Novoa RA; Honda K; Koon HB; Gerstenblith MR
J Am Acad Dermatol; 2012 Dec; 67(6):e271-2. PubMed ID: 23158633
[No Abstract] [Full Text] [Related]
57. Toxic epidermal necrolysis induced by vemurafenib after nivolumab failure.
Arenbergerova M; Mrazova I; Horazdovsky J; Sticova E; Fialova A; Arenberger P
J Eur Acad Dermatol Venereol; 2017 May; 31(5):e253-e254. PubMed ID: 27739125
[No Abstract] [Full Text] [Related]
58. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
[TBL] [Abstract][Full Text] [Related]
59. Case of successfully switching from nivolumab to vemurafenib with oral corticosteroids.
Imafuku K; Yoshino K; Yamaguchi K; Tsuboi S; Ohara K; Hata H
J Dermatol; 2018 Jun; 45(6):e156. PubMed ID: 29315740
[No Abstract] [Full Text] [Related]
60. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.
Alonso-Castro L; Ríos-Buceta L; Vano-Galvan S; Moreno C; Soria-Rivas A; Jaén P
J Am Acad Dermatol; 2013 Jul; 69(1):e28-9. PubMed ID: 23768302
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
